In Parkinson′s disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile are available. Our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine agonists.
1. Introduction
Four decades after its introduction, levodopa remains the most effective agent to improve motor symptoms in PD, but chronic use is associated with the emergence of motor fluctuations, defined as a loss of clinical benefit before the next levodopa dose (wearing off), abnormal involuntary movements (dystonia, chorea, and athetosis—collectively referred to as dyskinesia) [1, 2], and nonmotor complications, as behavioural and cognitive changes [3]. Levodopa is initially well tolerated in most of the cases and allows a substantial improvement of motor performances despite its erratic pharmacokinetics [1, 4]. With the disease progression, therapeutic window of levodopa narrows, and the duration of each dose shortens. Motor fluctuations usually precede dyskinesias [5], and it has been observed that the development of one is a risk factor for the development of the other [5].
Although more commonly associated with levodopa, dyskinesias can also occur with dopamine agonist monotherapy [6–8]. The development of dyskinesia in some patients treated with dopamine agonists that have relatively long half-lives (ropinirole, 6 h; pramipexole, 8 h) or very long half-lives (cabergoline, 68 h) suggests that, to some extent, even dopamine stimulation provided in a continuous fashion can cause dyskinesias.
2. Epidemiology and Clinical Aspects of Motor Complications
The three most important risk factors positively associated with increased occurrence of dyskinesias are younger age at disease onset [9, 10], longer disease duration [11, 12], and longer duration of pulsatile dopaminergic treatment (typically, levodopa) [13, 14]. The first two factors are interrelated and almost all patients with early-onset PD [15] develop dyskinesias, whereas they are less frequent in patients with late-onset PD [16]. PD patients with early disease onset have a high probability to carry mutations for monogenic PD forms, and therefore, early onset and genetic predisposition are two overlapping and possibly interrelated risk factors. Other risk factors associated with increased risk of dyskinesias are female gender [17, 18] and the occurrence of specific polymorphisms for dopamine receptors or dopamine transporters [19–21].
Dyskinesias more commonly appear as choreiform, but in some cases, they may resemble dystonia, myoclonus, or other movement disorders. Peak-dose dyskinesias are the most common type of dyskinesia. They occur during peaks of levodopa-derived dopamine in the brain, when the patient is otherwise experiencing a beneficial response (the “on” state). Peak-dose dyskinesias worsen with increases in dopaminergic dose and lessen with its reductions. In certain cases, dyskinesias seem to appear with a more particular pattern, as dyskinesia-improvement-dyskinesia. This is termed diphasic dyskinesia, and it tends to occur when levodopa-derived dopamine concentrations are increasing or decreasing, whereas the clinical condition of the patient turns “on” and “off” [22]. Diphasic dyskinesias are typically displayed with large-amplitude stereotypic, rhythmic, and repetitive movements, more often of the legs, that may be associated with Parkinsonian features in other body regions. In extreme cases, patients treated with levodopa can cycle between “on” periods, which are complicated by disabling dyskinesias, and “off” periods in which Parkinsonism is uncontrolled and the patient is akinetic and frozen.
Motor complications occur in about 50% of patients with PD who have been in therapy with levodopa for more than 5 years, and in almost 100% of patients with young-onset disease [23, 24]. Achieving an acceptable clinical control once these motor fluctuations have appeared is usually a relatively simple matter, nearing together the levodopa doses or adding medications that reduce “off” time. However, when a patient develops peak-dose dyskinesias too, it becomes difficult to smooth the clinical response. Although for many patients, dyskinesias are not disabling, they create a barrier to adequate treatment of fluctuations and Parkinsonian symptoms.
3. Pathophysiology of Dyskinesias
A primary condition in LID pathophysiology is the presence of dopaminergic cell loss in substantia nigra [25–27]. The nonappearance of dyskinesia in normal humans chronically treated with levodopa (i.e., mistaken diagnosis [28]) and its rapid emergence in PD patients either with late diagnosis or a young onset, where denervation is high at diagnosis [15, 29, 30], heavily support this theory. Moreover, the progression of nigral denervation seems to be closely related with the lowering of the dyskinesia onset threshold in MPTP-exposed primates [31]. Nonetheless, denervation cannot be the unique factor responsible for dyskinesia, whereas not all patients with advanced illness and extensive nigral denervation develop dyskinesia when treated with levodopa [32, 33]. Thus, a chronic dopaminergic stimulation on a denervated substantia nigra induces a process of sensitisation such that each following administration modifies the response to subsequent dopaminergic treatments. This process, called priming, increases over time of treatment the chance of eliciting dyskinesias and, once dyskinesias have been established, their severity. The priming process, which is responsible for the insidious evolution of dyskinesias over time of treatment, is associated with changes in receptors for dopamine or other neurotransmitters [34, 35]. A crucial role has been postulated for both dopamine receptors and NMDA glutamate receptors in the induction of priming; this mechanism could be regarded as an increased responsiveness of postsynaptic striatal dopamine receptors (mainly D1-like), which are activated in conjunction with glutamatergic inputs [1]. Dyskinesias are probably generated by a persistent enhancement of the responsiveness of striatal medium-sized spiny neurones to dopaminergic treatment. This is an aftermath of dopamine depletion and is associated with overexpression of specific components of the signal transduction machinery. If protracted, this condition may ultimately lead to long-term changes in gene expression, which will permanently affect the function of striatal medium spiny neurones [36]. Following priming, the development of dyskinesias largely depends on two additional factors, the pulsatile administration of levodopa (or another short-acting dopaminergic agent) and the severity of dopaminergic denervation in the striatum. The latter plays an important role in setting the threshold required in developing dyskinesias [37]. A direct relationship between the severity of striatal denervation and the time required to develop dyskinesias has been demonstrated in PD patients [38] and has been indirectly confirmed by the finding that patients with dopa-responsive dystonia, who have Parkinsonism without nigrostriatal denervation, uncommonly develop dyskinesias [39].
In early PD patients, levodopa-derived dopamine is packaged into synaptic vesicles by vesicular monoamine transporter 2 (VMAT-2), stored, and released in both tonic and phasic bursts in response to impulse flow [40, 41], in order to preserve dopamine receptors from levodopa plasma concentration fluctuations and, therefore, to maintain physiological dopaminergic transmission [42, 43]. With the progression of the disease, and the striatal dopaminergic cell loss, the formation of dopamine from levodopa and its storage capacity are increasingly compromised, and the response to levodopa becomes dominated by its pharmacokinetic characteristics and general bioavailability [4]. Thus, in advanced PD, peak concentrations of drug in plasma become coincidental with the expression of dyskinesia. As observed in animal models, the continuous release of dopamine leads to improvements in motor function and, together, to a marked reduction in the expression of involuntary movements [44]. These studies support the clinical findings that the continuous intravenous or intraduodenal administration of levodopa or the continuous subcutaneous or intravenous infusion of apomorphine results in improved motor response but also with a marked reduction of dyskinesia [45, 46].
Other mechanisms are involved to explain the underlying cause and expression of dyskinesia. Although dopamine agonists when used as monotherapy in early PD are associated to a lower incidence of dyskinesia, involuntary movements are still observed, reflecting some kind of activity at the postsynaptic dopamine receptor level, as dopamine agonists are not dependent on the presence of presynaptic terminals.
Subtle changes in D1 and D2 receptor density as well as the complex interaction between receptor activation and synaptic plasticity [1] have been proposed as playing significant roles in dyskinesia induction and expression. Although the exact molecular mechanisms of LID still remain to be fully elucidated, exaggerated signalling of the striatal D1 [47–49], the reduction of the modulating function of D2/D3 receptors [42, 43, 50–52], and the interaction between D2 and A2A adenosine receptors [53] have been implicated in both rodents and primates, suggesting that a normalisation of signalling may be beneficial in the treatment of dyskinesia.
In clinical practice, postsynaptic mechanisms can be partially explained by the dopamine agonists capability to prime for involuntary movements. Switching from a chronic dopamine agonist administration that usually results in a low expression and intensity of dyskinesia to an equivalent dose of levodopa in fact immediately results in the appearance of dramatic involuntary movements [54, 55]. These findings suggest that dopamine agonists principally prime for, but less commonly express dyskinesia. Vice versa, when considering the expression of dyskinesia in patients with PD with a history of levodopa exposure, switching to a dopamine agonist after the introduction of levodopa, established dyskinesia still occurred [56]. Moreover, patients receiving a combination of levodopa and the dopamine D2/D3 agonist pramipexole showed a level of dyskinesia that was greater than the additive effect of the individual drug [57]. Once established, dopamine agonists produce the same pattern of dyskinesia although its intensity is reduced, suggesting that agonists do not express dyskinesia to the same extent as levodopa [54, 55, 58]. Both the lower priming for dyskinesia and the lower expression of involuntary movements by dopamine agonists may be a reflection of their more specific pharmacology compared to levodopa.
4. Reducing or Delaying Parkinsonian Dyskinesias
Any type of exogenous dopaminergic stimulation in a denervated striatum can cause dyskinesias [59], but pulsatile stimulation produced by short-acting drugs (as typically occurs with levodopa) particularly favours their occurrence [60]. The expression LID is still currently used, although levodopa is not the only drug causing dyskinesias in PD patients [61]. Based on published series, it has been estimated that PD patients treated for less than 5 years have a 11% risk of developing dyskinesias, those treated for 6–9 years have a risk of 32%, whereas patients treated for more than 10 years have a risk of 89% [13].
Levodopa, however, seems to be the most important factor in inducing dyskinesia expression in chronically treated PD patients; therefore, it appears that the benefit of initial treatment with a dopamine agonist in lowering the incidence of dyskinesias is related to the ability of the agonist to delay the need for levodopa [12, 62]. Moreover, experimental data suggest that the administration of long-acting dopamine agonists results in significantly less dyskinesia than does levodopa [63, 64] and other short-acting agents administrated in a pulsatile fashion [65]. However, once a long-acting agonist is administered to animals already primed to exhibit dyskinesias with levodopa, the resultant dyskinesias are comparable to those seen in the levodopa group [63]. Clinical studies randomly assigning patients to initial treatment with a dopamine agonist or levodopa have shown a lower risk for dyskinesias in the groups treated with pramipexole [7], ropinirole [8, 12], bromocriptine [66, 67], pergolide [68], and cabergoline [6]; nevertheless, once levodopa was added, the rate of development of dyskinesias was similar in both groups.
One therapeutic strategy that has been tried in this sense is to use higher doses of a dopamine agonist to reduce both the total daily levodopa dose and its frequency [69] or to gradually substitute a dopamine agonist for levodopa [70]. Unfortunately, these strategies are unsatisfactory and typically reduce dyskinesias at the expense of less control of Parkinsonian symptoms. Indeed, the evidence that early levodopa exposure adversely affects the course of disease and leads to disabling dyskinesias and motor fluctuations constituted the rationale for the initial treatment with dopamine agonist.
5. Different Profile and Efficacy of Dopamine Agonists in Reducing Dyskinesia
In order to create a valid alternative to levodopa, and with the aim of eliminating its related complications, many different drugs acting on dopaminergic receptors have been developed and studied during the last years. They have different metabolism, plasma half-life, affinity to receptors subtypes, excretion, and routes of administration (Table 1). Moreover, these drugs have different efficacies on reducing the incidence of dyskinesia, improving motor symptoms, and reducing the daily levodopa dose (Table 2, Figure 1).
Table 1.
Pharmacological characteristics of dopamine agonists.
Effects of dopamine agonists on (a) reducing off time, (b) reducing levodopa daily dose, and (c) inducing dyskinesia.
Initially dopamine agonists have been used as adjuvant therapy to improve levodopa-induced complications, but once their effects on delaying the need for levodopa have been demonstrated, they have often been prescribed before the introduction of levodopa. Patients receiving dopamine agonists rather than levodopa as initial monotherapy showed a reduced risk for developing dyskinesias [7, 8, 12, 62, 72–76] (Table 3).
Table 3.
Series on adjuvant therapy with dopamine agonists*. In italic, dyskinesia evaluation.
N: 23; not optimally controlled with levodopa. Mean duration of PD: 8.7 y
Bromocriptine (n = 12) versus placebo (n = 11)
Disability
*Performed on PD patients, parallel groups, double blind.
MFs: motor fluctuations; SE: side effects.
5.1. Dopamine Agonists Monotherapy and the Risk of Dyskinesia
The CALM-PD trial (Comparison of the Agonist Pramipexole versus Levodopa on Motor Complications of Parkinson’s Disease) was a randomised controlled trial evaluating the risk of developing dyskinesias in patients with early PD initially treated with either pramipexole or levodopa. After 24 months, pramipexole-treated patients were receiving pramipexole plus levodopa, compared with levodopa alone. A minority of pramipexole-treated patients reached the endpoint of time to first occurrence of wearing off, dyskinesias, or on-off motor fluctuations (27.8% versus 50.7%, P < 0.001). Moreover, a significantly lower incidence of dyskinesias (9.9% versus 30.7%, P < 0.001) also has been demonstrated in patients in the pramipexole group. However, after a mean 6-year followup, >90% of patients were receiving levodopa therapy regardless of their initial treatment assignment. Compared to those taking pramipexole, patients initially treated with levodopa had significantly more dyskinesias (20.4% versus 36.8%), but there was no difference between groups in the incidence of disabling or painful dyskinesias [62, 74]. Interestingly, 5 subjects taking pramipexole developed dyskinesias before the supplemental levodopa, and 4 of them had no prior levodopa exposure [73]. No significant difference in the Lang-Fahn activities of daily living dyskinesia score was observed (1.3 versus 1.1 with pramipexole, P < 0.06) [7, 62, 72–74].
In a randomised, double-blind 5-year study of patients with early PD, the risk of developing dyskinesias after initial monotherapy with ropinirole was less than with levodopabenserazide (hazard ratio (HR), 2.82 (1.78, 4.44); P < 0.001) [8]. However, many of these patients eventually required supplemental levodopa to control the symptoms of the disease [8, 12]. When patients receiving ropinirole monotherapy required the addition of levodopa, the risk for developing dyskinesias increased and then did not differ significantly from that associated with levodopa alone [12]. The use of ropinirole as monotherapy, with only later addition of levodopa, delayed the onset of dyskinesias by up to 3 years, although it was associated with a higher incidence of neuropsychiatric complications than levodopa monotherapy.
Apomorphine, a subcutaneous nonergolinic dopaminergic agent, has been studied in 2 retrospective chronic monotherapy trials in which no oral anti-parkinsonian therapies were permitted from the time the pump was turned on in the morning until it was turned off in the evening [77, 78]. The mean maximum reduction of dyskinesia per patient was 64% (P < 0.005), and the mean time to achieve maximal dyskinesia improvement was 12.1 months.
Lisuride, another subcutaneously administered dopamine agonist, given as a continuous daytime infusion via pump, has been utilised as a strategy for minimising dyskinesias in 40 patients with advanced, levodopa-responsive PD characterised by motor fluctuations and dyskinesias [109]. After 4 years, the lisuride-treated patients had improved their baseline dyskinesia scores (measured by AIMS) by 49% (P < 0.0001), whereas the levodopa-treated patients had worsened their scores by 59% (P < 0.0001).
5.2. Long-Acting Dopamine Agonists and the Risk of Dyskinesia
In animal-model studies, the long-acting dopamine agonists have been demonstrated to prevent or reduce the onset time for LIDs. In a study of monkeys with MPTP-induced parkinsonism, small doses of subcutaneously administered cabergoline, a D2-selective dopamine agonist with a relatively long half-life, were added as adjuvant therapy to orally administered levodopa/benserazide (100/25 mg) for 1 month, showing significantly lower dyskinesia scores (sum for all body segments) than when levodopa/benserazide was given alone for 1 month (P < 0.01).
A report on the effect of cabergoline compared to levodopa showed a reduced incidence of dyskinesias [110]. Nevertheless, more recently, an increased incidence of dyskinesia and confusion in patients treated with bromocriptine was reported [111].
5.3. Differences among Drugs in Adjuvant Therapy
A recent systematic meta-analysis, which performs indirect comparisons among three classes of drugs, including nondopaminergic agents as catechol-O-methyl transferase inhibitors (COMTIs) or monoamine oxidase type B inhibitors (MAOBIs), used as add-on (adjuvant) treatment to levodopa therapy in PD patients with motor complications, suggests that dopamine agonists may provide more effective symptomatic control [112].
5.3.1. Off-Time Reduction
There is no (or little) evidence of a difference across the different dopamine agonists for the overall reduction in off-time [pramipexole (−1.81 hours/day, CI −2.19 to −1.43; P < 0.00001); bromocriptine (−1.78 hours/day, CI −2.91 to −0.65; P = 0.002); pergolide (−1.60 hours/day, CI −2.57 to −0.63; P = 0.001); cabergoline (−1.29 hours/day, CI −1.89 to −0.69; P < 0.0001); ropinirole (−0.93 hours/day, CI −1.53 to −0.33; P = 0.002)] [112].
5.3.2. Levodopa Daily Dose Reduction
The largest reduction was with pergolide (−183.90 mg/day, CI −259.09 to −72.71; P = 0.001), though this was based on data from just one trial [71]. Cabergoline reduced the required levodopa dose by 149.60 mg/day (CI −208.79 to −90.41; P < 0.00001), ropinirole by 119.81 mg/day (CI −150.63 to −89.00; P < 0.00001), pramipexole by 114.82 mg/day (CI −143.01 to −86.64; P < 0.00001), and bromocriptine by 52.17 mg/day (CI −95.16 to −9.18; P = 0.02) [112].
5.3.3. UPDRS Scores Improvement
The agonist pramipexole appeared to produce larger improvements for UPDRS motor score (−6.31 points, CI −7.69 to −4.93; P < 0.00001) compared to ropinirole (UPDRS motor: −4.80 points, CI −7.32 to −2.28; P = 0.0002) and cabergoline (UPDRS motor: −1.74 points, CI −3.78 to 0.30; P = 0.09) [112].
5.3.4. Incidence of Dyskinesia
The analysis included 6476 participants, which represented 85% of the 7590 randomised participants included in the meta-analysis. Compared to placebo, the incidence of dyskinesia was increased with adjuvant therapy. The incidence of dyskinesia was greatest with pergolide (OR 4.64, CI 3.09 to 6.97; P < 0.00001), although the data were obtained from just one trial [71], followed by ropinirole (OR 3.21, CI 1.98 to 5.21; P < 0.00001), pramipexole (OR 2.63, CI 2.01 to 3.42; P < 0.00001), bromocriptine (OR 2.52, CI 1.42 to 4.48; P = 0.002), and cabergoline (OR 1.44, CI 0.96 to 2.16; P = 0.08) [112].
Though this meta-analysis indirectly compares several series on dopaminergic agents as adjuvant treatment, the need of large randomised studies that directly compare different agents administered as monotherapy with patient-rated overall quality of life and health economic measures as primary outcomes is recommended.
6. Alternative Treatments to Reduce Dyskinesia
As seen earlier, the primary therapeutic strategy for managing LIDs in PD patients is to delay their occurrence through delaying the introduction of levodopa therapy administering dopaminergic agents.
Once dyskinesias have occurred, other strategies should be attempted: (1) substitution of immediate release for controlled-release levodopa. The immediate-release preparation is easier to adjust, as onset of its effects is sooner, and duration of action (and dyskinesias) is shorter than with controlled-release preparations. For the same reason, agents that prolong the half-life of levodopa, such as entacapone, should be stopped; (2) discontinuation of other therapy that may embitter dyskinesias, as dopamine agonists or other factors delaying dopamine degradation as selegiline and rasagiline; (3) incrementation of the number of administrations of levodopa, in lower doses; (4) addition of an antidyskinetic agent as amantadine, an NMDA receptor antagonist. Diphasic dyskinesias that may manifest at the beginning and the end of a dosing cycle should be managed by utilising more frequent doses of levodopa, and the therapy should be sewed on the patient [113].
6.1. Amantadine
The NMDA receptor-binding and neurotoxic effects of excessive glutamate have led to the hypothesis that an NMDA antagonist may have antidyskinetic effects and reduce the severity of LIDs. Amantadine has been studied as adjuvant treatment in levodopa-treated patients experiencing motor complications, including dyskinesias, with the aim of reducing these effects without worsening Parkinsonian symptoms [114–117]. Three randomized placebo-controlled crossover clinical studies in a group of 53 PD patients showed a reduction (up to 60%) in the severity of LIDs after challenge with acute levodopa administration, without impacting the beneficial effects of levodopa on motor function.
6.2. Clozapine
It is an atypical antipsychotic that has been assessed for the treatment of drug-induced psychosis in PD. It may also be effective in decreasing dyskinesias [70], and a few studies have focused on its antidyskinetic effect [118, 119].
6.3. Intraduodenal Levodopa
It provides direct delivery of levodopa to the duodenum and jejunum. The method involves insertion of a permanent access tube in the abdominal wall by percutaneous endoscopic gastrostomy. Several clinical studies have been conducted using this approach, demonstrating significant reductions in “off” time and dyskinesia after 6 months. It may be an option for patients with marked fluctuations and dyskinesia in whom deep-brain stimulation (DBS) is contraindicated or not possible due to advanced age, or it may provide an alternative to DBS.
6.4. Surgical Treatment
Patients with PD who may benefit from surgery include those who have substantial dyskinesias unresponsive to medication adjustments, are levodopa responsive, do not have dementia, and do not have neuropsychiatric impairment [80]. DBS is the most frequently performed surgery for PD in North America [80]. In patients with advanced PD, DBS of the globus pallidus interna (GPi) or the subthalamic nucleus (STN) has been shown to reduce dyskinesia severity by up to 89% [120, 121] and to reduce the duration of dyskinesias by 86% [122]. It provides significant improvement in Parkinsonian motor features and allows a reduction of dyskinesias, in part through the subsequent reduction of levodopa [123, 124].
1Calabresi P.,
Filippo M. D.,
Ghiglieri V.,
Tambasco N., and
Picconi B., Levodopa-induced dyskinesias in patients with Parkinson′s disease: filling the bench-to-bedside gap, The Lancet Neurology. (2010) 9, no. 11, 1106–1117, 2-s2.0-77957966489, https://doi.org/10.1016/S1474-4422(10)70218-0.
2Stocchi F.,
Tagliati M., and
Olanow C. W., Treatment of levodopa-induced motor complications, Movement Disorders. (2008) 23, no. supplement 3, S599–S612, 2-s2.0-53149141398, https://doi.org/10.1002/mds.22052.
3Tambasco N.,
Belcastro V.,
Gallina A.,
Castrioto A.,
Calabresi P., and
Rossi A., Levodopa-induced breathing, cognitive and behavioral changes in Parkinson′s disease, Journal of Neurology. (2011) 2296–2299, 2-s2.0-79957865187, https://doi.org/10.1007/s00415-011-6119-5.
4Nutt J. G., Pharmacokinetics and pharmacodynamics of levodopa, Movement Disorders. (2008) 23, no. supplement 3, S580–S584, 2-s2.0-53149144682, https://doi.org/10.1002/mds.22037.
5Hauser R. A.,
McDermott M. P., and
Messing S., Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease, Archives of Neurology. (2006) 63, no. 12, 1756–1760, 2-s2.0-33845549022, https://doi.org/10.1001/archneur.63.12.1756.
6Bracco F.,
Battaglia A.,
Chouza C.,
Dupont E.,
Gershanik O.,
Masso J. F. M., and
Montastruc J. L., The long-acting dopamine receptor agonist cabergoline in early Parkinson′s disease: final results of a 5-year, double-blind, levodopa-controlled study, CNS Drugs. (2004) 18, no. 11, 733–746, 2-s2.0-4544226873, https://doi.org/10.2165/00023210-200418110-00003.
7The Parkinson Study Group, Pramipexole vs levodopa as initial treatment for Parkinson Disease: a 4-year randomized controlled trial, Archives of Neurology. (2004) 61, no. 7, 1044–1053, 2-s2.0-3142733662, https://doi.org/10.1001/archneur.61.7.1044.
8Rascol O.,
Brooks D. J.,
Korczyn A. D.,
De Deyn P. P.,
Clarke C. E., and
Lang A. E., A five-year study of the incidence of dyskinesia in patients with early Parkinson′s disease who were treated with ropinirole or levodopa, The New England Journal of Medicine. (2000) 342, no. 20, 1484–1491, 2-s2.0-0034682308, https://doi.org/10.1056/NEJM200005183422004.
9Kostic V.,
Przedborski S.,
Flaster E., and
Sternic N., Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson′s disease, Neurology. (1991) 41, no. 2 I, 202–205, 2-s2.0-0026036024.
10Schrag A.,
Hovris A.,
Morley D.,
Quinn N., and
Jahanshahi M., Young- versus older-onset Parkinson′s disease: impact of disease and psychosocial consequences, Movement Disorders. (2003) 18, no. 11, 1250–1256, 2-s2.0-1342347420, https://doi.org/10.1002/mds.10527.
11The Parkinson Study Group, Impact of deprenyl and tocopherol treatment on Parkinson′s disease in DATATOP subjects not requiring levodopa, Annals of Neurology. (1996) 39, no. 1, 29–36, 2-s2.0-0030042620.
12Rascol O.,
Brooks D. J.,
Korczyn A. D.,
De Deyn P. P.,
Clarke C. E.,
Lang A. E.,
Abdalla M.,
Harmant J.,
Jacquy J.,
King D.,
Martin W.,
Destee A.,
Durif F.,
Aharon-Peretz J.,
Reches A.,
Bergamasco B.,
Bracco F.,
Frattolla L.,
Nordera P.,
Pezzoli G.,
Scarlato G.,
Stocchi F.,
Hovestadt A.,
Abbott R.,
Bakheit M.,
Boddie G.,
Brooks D. J.,
Clarke C. E.,
Corston R.,
Hawkes C.,
Kennard C.,
Loizou L.,
McLellan L.,
Park D.,
Sagar H.,
Spokes E.,
Ward C., and
Wroe S. V., Development of dyskinesias in a 5-year trial and ropinirole and L-dopa, Movement Disorders. (2006) 21, no. 11, 1844–1850, 2-s2.0-33845188900, https://doi.org/10.1002/mds.20988.
13Fabbrini G.,
Brotchie J. M.,
Grandas F.,
Nomoto M., and
Goetz C. G., Levodopa-induced dyskinesias, Movement Disorders. (2007) 22, no. 10, 1379–1389, 2-s2.0-34548030225, https://doi.org/10.1002/mds.21475.
14Schrag A. and
Quinn N., Dyskinesias and motor fluctuations in Parkinson′s disease: a community-based study, Brain. (2000) 123, no. 11, 2297–2305, 2-s2.0-0033768218.
15Schrag A. and
Schott J. M., Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, The Lancet Neurology. (2006) 5, no. 4, 355–363, 2-s2.0-33644971837, https://doi.org/10.1016/S1474-4422(06)70411-2.
16Kumar N.,
Van Gerpen J. A.,
Bower J. H., and
Ahlskog J. E., Levodopa-dyskinesia incidence by age of Parkinson′s disease onset, Movement Disorders. (2005) 20, no. 3, 342–344, 2-s2.0-18144423079, https://doi.org/10.1002/mds.20360.
17Lyons K. E.,
Hubble J. P.,
Tröster A. I.,
Pahwa R., and
Koller W. C., Gender differences in Parkinson′s disease, Clinical Neuropharmacology. (1998) 21, no. 2, 118–121, 2-s2.0-0031954286.
18Zappia M.,
Annesi G.,
Nicoletti G.,
Arabia G.,
Annesi F.,
Messina D.,
Pugliese P.,
Spadafora P.,
Tarantino P.,
Carrideo S.,
Civitelli D.,
De Marco E. V.,
Cirò-Candiano I. C.,
Gambardella A., and
Quattrone A., Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study, Archives of Neurology. (2005) 62, no. 4, 601–605, 2-s2.0-20144388439, https://doi.org/10.1001/archneur.62.4.601.
19Gilgun-Sherki Y.,
Djaldetti R.,
Melamed E., and
Offen D., Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson′s disease, Pharmacogenomics Journal. (2004) 4, no. 5, 291–306, 2-s2.0-5144226037, https://doi.org/10.1038/sj.tpj.6500260.
20Kaiser R.,
Hofer A.,
Grapengiesser A.,
Gasser T.,
Kupsch A.,
Roots I., and
Brockmöller J., L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism, Neurology. (2003) 60, no. 11, 1750–1755, 2-s2.0-0037777723.
21Oliveri R. L.,
Annesi G.,
Zappia M.,
Civitelli D.,
Montesanti R.,
Branca D.,
Nicoletti G.,
Spadafora P.,
Pasqua A. A.,
Cittadella R.,
Andreoli V.,
Gambardella A.,
Aguglia U., and
Quattrone A., Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD, Neurology. (1999) 53, no. 7, 1425–1430, 2-s2.0-0032589720.
25Boyce S.,
Clarke C. E.,
Luquin R.,
Peggs D.,
Robertson R. G.,
Mitchell I. J.,
Sambrook M. A., and
Crossman A. R., Induction of chorea and dystonia in parkinsonian primates, Movement Disorders. (1990) 5, no. 1, 3–7, 2-s2.0-0025266077.
27Boraud T.,
Bezard E.,
Bioulac B., and
Gross C. E., Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey, Brain. (2001) 124, 546–557, 2-s2.0-0035104574.
28Jankovic J.,
Rajput A. H.,
McDermott M. P., and
Perl D. P., The evolution of diagnosis in early Parkinson disease, Archives of Neurology. (2000) 57, no. 3, 369–372, 2-s2.0-0034063907.
29Schrag A.,
Ben-Shlomo Y.,
Brown R.,
Marsden C. D., and
Quinn N., Young-onset Parkinson′s disease revisited—clinical features, natural history, and mortality, Movement Disorders. (1998) 13, no. 6, 885–894, 2-s2.0-0031770529.
30Sossi V.,
De La Fuente-Fernández R.,
Schulzer M.,
Adams J., and
Stoessl J., Age-related differences in levodopa dynamics in Parkinson′s: implications for motor complications, Brain. (2006) 129, 1050–1058, 2-s2.0-33645055382, https://doi.org/10.1093/brain/awl028.
31Di Monte D. A.,
McCormack A.,
Petzinger G.,
Janson A. M.,
Quik M., and
Langston W. J., Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model, Movement Disorders. (2000) 15, no. 3, 459–466.
32Linazasoro G., New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity, Trends in Pharmacological Sciences. (2005) 26, no. 8, 391–397, 2-s2.0-22844435191, https://doi.org/10.1016/j.tips.2005.06.007.
33Linazasoro G.,
Van Blercom N.,
Bergaretxe A.,
Fernández Manchola I.,
Laborda E., and
Ruiz Ortega J. A., Levodopa-induced dyskinesias in parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study, Clinical Neuropharmacology. (2009) 32, no. 6, 326–329, 2-s2.0-74249120624, https://doi.org/10.1097/WNF.0b013e3181b52792.
34Gerfen C. R.,
Engber T. M.,
Mahan L. C.,
Susel Z.,
Chase T. N.,
Monsma F. J., and
Sibley D. R., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science. (1990) 250, no. 4986, 1429–1432, 2-s2.0-0025572196.
35Nash J. E. and
Brotchie J. M., A common signaling pathway for striatal NMDA and adenosine A(2a) receptors: implications for the treatment of Parkinson′s disease, Journal of Neuroscience. (2000) 20, no. 20, 7782–7789, 2-s2.0-0034667715.
36Santini E.,
Valjent E., and
Fisone G., Parkinson′s disease: levodopa-induced dyskinesia and signal transduction, FEBS Journal. (2008) 275, no. 7, 1392–1399, 2-s2.0-40749086042, https://doi.org/10.1111/j.1742-4658.2008.06296.x.
37Boyce S.,
Rupniak N. M. J.,
Steventon M. J., and
Iversen S. D., Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys, Clinical Neuropharmacology. (1990) 13, no. 5, 448–458, 2-s2.0-0025140869.
38Kumar A.,
Mann S.,
Sossi V.,
Ruth T. J.,
Stoessl A. J.,
Schulzer M., and
Lee C. S., [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson′s disease, Brain. (2003) 126, no. 12, 2648–2655, 2-s2.0-0344012036, https://doi.org/10.1093/brain/awg270.
39de la Fuente-Fernández R., Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations, Clinical Neuropharmacology. (1999) 22, no. 4, 216–219, 2-s2.0-0343986283.
40Fleckenstein A. E.,
Volz T. J., and
Hanson G. R., Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications, Neuropharmacology. (2009) 56, no. supplement 1, 133–138, 2-s2.0-58049134909, https://doi.org/10.1016/j.neuropharm.2008.07.002.
41Dreyer J. K.,
Herrik K. F.,
Berg R. W., and
Hounsgaard J. D., Influence of phasic and tonic dopamine release on receptor activation, Journal of Neuroscience. (2010) 30, no. 42, 14273–14283, 2-s2.0-77958521455, https://doi.org/10.1523/JNEUROSCI.1894-10.2010.
42Obeso J. A.,
Olanow C. W., and
Nutt J. G., Levodopa motor complications in Parkinson′s disease, Trends in Neurosciences. (2000) 23, no. 10, S2–S7, 2-s2.0-0033695441.
43Obeso J. A.,
Rodriguez-Oroz M. C.,
Rodriguez M.,
DeLong M. R., and
Olanow C. W., Pathophysiology of levodopa-induced dyskinesias in Parkinson′s disease: problems with the current model, Annals of Neurology. (2000) 47, no. supplement 1, S22–S34, 2-s2.0-0034109592.
44Björklund T.,
Carlsson T.,
Cederfjäll E. A.,
Carta M., and
Kirik D., Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson′s disease, Brain. (2010) 133, 496–511, 2-s2.0-77249179185, https://doi.org/10.1093/brain/awp314.
45Mouradian M. M.,
Juncos J. L.,
Fabbrini G., and
Chase T. N., Motor fluctuations in Parkinson′s disease: pathogenetic and therapeutic studies, Annals of Neurology. (1987) 22, no. 4, 475–479, 2-s2.0-0023627787.
46Stocchi F., The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson′s disease, Parkinsonism and Related Disorders. (2009) 15, no. supplement 3, S68–S71, 2-s2.0-71849108352, https://doi.org/10.1016/S1353-8020(09)70784-9.
47Bezard E.,
Brotchie J. M., and
Gross C. E., Pathophysiology of levodopa-induced dyskinesia: potential for new therapies, Nature Reviews Neuroscience. (2001) 2, no. 8, 577–588, 2-s2.0-0035434121, https://doi.org/10.1038/35086062.
48Cenci M. A.,
Lee C. S., and
Björklund A., L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA, European Journal of Neuroscience. (1998) 10, no. 8, 2694–2706, 2-s2.0-0031925945, https://doi.org/10.1046/j.1460-9568.1998.00285.x.
49Fiorentini C.,
Rizzetti M. C.,
Busi C.,
Bontempi S.,
Collo G.,
Spano P., and
Missale C., Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat, Molecular Pharmacology. (2006) 69, no. 3, 805–812, 2-s2.0-33644841226, https://doi.org/10.1124/mol.105.016667.
50Missale C.,
Nash S. R.,
Robinson S. W.,
Jaber M., and
Caron M. G., Dopamine receptors: from structure to function, Physiological Reviews. (1998) 78, no. 1, 189–225, 2-s2.0-6844250767.
51Le Moine C. and
Bloch B., D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum, Journal of Comparative Neurology. (1995) 355, no. 3, 418–426, 2-s2.0-0029002052.
52Morelli M. and
DiChiara G., Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning, European Journal of Pharmacology. (1987) 141, no. 1, 101–107, 2-s2.0-0023205239.
53Xiao D.,
Bastia E.,
Xu Y. H.,
Benn C. L.,
Cha J. H. J.,
Peterson T. S.,
Chen J. F., and
Schwarzschild M. A., Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice, Journal of Neuroscience. (2006) 26, no. 52, 13548–13555, 2-s2.0-33845899095, https://doi.org/10.1523/JNEUROSCI.3554-06.2006.
54Smith L. A.,
Jackson M. J.,
Johnston L.,
Kuoppamaki M.,
Rose S.,
Al-Barghouthy G.,
Del Signore S., and
Jenner P., Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates, Clinical Neuropharmacology. (2006) 29, no. 3, 112–125, 2-s2.0-33746417219, https://doi.org/10.1097/01.WNF.0000220818.71231.DF.
55Jackson M. J.,
Smith L. A.,
Al-Barghouthy G.,
Rose S., and
Jenner P., Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets, Experimental Neurology. (2007) 204, no. 1, 162–170, 2-s2.0-33847315060, https://doi.org/10.1016/j.expneurol.2006.10.005.
56Cotzias G. C.,
Papavasiliou P. S., and
Tolosa E. S., Treatment of Parkinson′s disease with aporphrines. Possible role of growth hormone, The New England Journal of Medicine. (1976) 294, no. 11, 567–572, 2-s2.0-0017239765.
57Brodsky M. A.,
Park B. S., and
Nutt J. G., Effects of a dopamine agonist on the pharmacodynamics of levodopa in parkinson disease, Archives of Neurology. (2010) 67, no. 1, 27–32, 2-s2.0-74949130888, https://doi.org/10.1001/archneurol.2009.287.
58Stockwell K. A.,
Scheller D. K. A.,
Smith L. A.,
Rose S.,
Iravani M. M.,
Jackson M. J., and
Jenner P., Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets, Experimental Neurology. (2010) 221, no. 1, 79–85, 2-s2.0-72749110467, https://doi.org/10.1016/j.expneurol.2009.10.004.
59Linazasoro G., Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial, Archives of Neurology. (2007) 64, no. 1, 137–140, 2-s2.0-33846096265, https://doi.org/10.1001/archneur.64.1.137.
61Metman L. V.,
Konitsiotis S., and
Chase T. N., Pathophysiology of motor response complications in Parkinson′s disease: hypotheses on the why, where, and what, Movement Disorders. (2000) 15, no. 1, 3–8.
62Constantinescu R.,
Romer M.,
McDermott M. P.,
Kamp C., and
Kieburtz K., Impact of pramipexole on the onset of levodopa-related dyskinesias, Movement Disorders. (2007) 22, no. 9, 1317–1319, 2-s2.0-34548234244, https://doi.org/10.1002/mds.21292.
63Pearce R. K. B.,
Banerji T.,
Jenner P., and
Marsden C. D., De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in the MPTP-treated marmoset, Movement Disorders. (1998) 13, no. 2, 234–241, 2-s2.0-0031930772, https://doi.org/10.1002/mds.870130207.
64Maratos E. C.,
Jackson M. J.,
Pearce R. K. B., and
Jenner P., Antiparkinsonian activity and dyskinesia risk of ropinirole and levodopa combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus), Movement Disorders. (2001) 16, no. 4, 631–641, 2-s2.0-0035412883, https://doi.org/10.1002/mds.1149.
65Blanchet P. J.,
Calon F.,
Morissette M.,
Goulet M.,
Grondin R.,
Lévesque D.,
Bédard P. J., and
Di Paolo T., Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model, Advances in Neurology. (2001) 86, 337–344, 2-s2.0-0035231227.
66Hely M. A.,
Morris J. G. L.,
Reid W. G. J.,
O′Sullivan D. J.,
Williamson P. M.,
Rail D.,
Broe G. A., and
Margrie S., The Sydney multicentre study of Parkinson′s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa, Journal of Neurology Neurosurgery and Psychiatry. (1994) 57, no. 8, 903–910, 2-s2.0-0027931399.
67Lees A. J.,
Katzenschlager R.,
Head J., and
Ben-Shlomo Y., Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial, Neurology. (2001) 57, no. 9, 1687–1694, 2-s2.0-0035856448.
68Oertel W. H.,
Wolters E.,
Sampaio C.,
Gimenez-Roldan S.,
Bergamasco B.,
Dujardin M.,
Grosset D. G.,
Arnold G.,
Leenders K. L.,
Hundemer H. P.,
Lledó A.,
Wood A.,
Frewer P., and
Schwarz J., Pergolide versus levodopa monotherapy in early Parkinson′s disease patients: The PELMOPET study, Movement Disorders. (2006) 21, no. 3, 343–353, 2-s2.0-33645543539, https://doi.org/10.1002/mds.20724.
69Obeso J. A.,
Rodriguez-Oroz M. C., and
Zamarbide I., A. H. V. Schapira and C. W. Olanow, Clinical features, pathophysiology, and management of motor complications in Parkinson′s disease, Principles of Treatment in Parkinson′s Disease, 2005, Butterworth Heinemann Elsevier, Philadelphia, Pa, USA, 99–112.
70Nirenberg M. J. and
Fahn S., A. H. V. Schapira and C. W. Olanow, The role of levodopa and catechol-o-methyltransferase inhibitors, Principles of Treatment in Parkinson′s Disease, 2005, Butterworth Heinemann Elsevier, Philadelphia, Pa, USA, 3–16.
71Olanow C. W.,
Fahn S.,
Muenter M.,
Klawans H.,
Hurtig H.,
Stern M.,
Shoulson I.,
Kurlan R.,
Grimes J. D.,
Jankovic J.,
Hoehn M.,
Markham C. H.,
Duvoisin R.,
Reinmuth O.,
Leonard H. A.,
Ahlskog E.,
Feldman R.,
Hershey L., and
Yahr M. D., A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson′s disease, Movement Disorders. (1994) 9, no. 1, 40–47, 2-s2.0-0028054876, https://doi.org/10.1002/mds.870090107.
72Parkinson Study Group, A randomized controlled trial comparing pramipexole with levodopa in early Parkinson′s disease: design and methods of the CALM-PD study, Clinical Neuropharmacology. (2000) 23, no. 1, 34–44.
73Parkinson Study Group, Pramipexole versus levodopa as initial treatment for Parkinson disease: a randomized controlled trial, The Journal of the American Medical Association. (2000) 284, no. 15, 1931–1938.
74Parkinson Study Group CALM Cohort Investigators, Long-term effect of initiating pramipexole versus levodopa in early Parkinson disease, Archives of Neurology. (2009) 66, 563–570.
75Hauser R. A.,
Rascol O.,
Korczyn A. D.,
Stoessl A. J.,
Watts R. L.,
Poewe W.,
De Deyn P. P., and
Lang A. E., Ten-year follow-up of Parkinson′s disease patients randomized to initial therapy with ropinirole or levodopa, Movement Disorders. (2007) 22, no. 16, 2409–2417, 2-s2.0-38549168908, https://doi.org/10.1002/mds.21743.
76Watts R. L.,
Lyons K. E.,
Pahwa R.,
Sethi K.,
Stern M.,
Hauser R. A.,
Olanow W.,
Gray A. M.,
Adams B., and
Earl N. L., Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson′s disease, Movement Disorders. (2010) 25, no. 7, 858–866, 2-s2.0-77951941921, https://doi.org/10.1002/mds.22890.
77Colzi A.,
Turner K., and
Lees A. J., Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson′s disease, Journal of Neurology Neurosurgery and Psychiatry. (1998) 64, no. 5, 573–576, 2-s2.0-0031923068.
78Manson A. J.,
Turner K., and
Lees A. J., Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson′s disease: long-term follow-up study of 64 patients, Movement Disorders. (2002) 17, no. 6, 1235–1241, 2-s2.0-0036869028, https://doi.org/10.1002/mds.10281.
79Poewe W. H.,
Rascol O.,
Quinn N.,
Tolosa E.,
Oertel W. H.,
Martignoni E.,
Rupp M., and
Boroojerdi B., Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson′s disease: a double-blind, double-dummy, randomised controlled trial, The Lancet Neurology. (2007) 6, no. 6, 513–520, 2-s2.0-34248372064, https://doi.org/10.1016/S1474-4422(07)70108-4.
80Pahwa R.,
Stacy M. A.,
Elmer L. W., and
Isaacson S. H., Ropinirole 24-hour prolonged release provides efficacy as early as week 2 when used as adjunctive therapy to levodopa in patients with advanced Parkinson′s disease, Movement Disorders. (2006) 21, no. supplement 15.
81Pahwa R.,
Stacy M. A.,
Factor S. A.,
Lyons K. E.,
Stocchi F.,
Hersh B. P.,
Elmer L. W.,
Truong D. D., and
Earl N. L., Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease, Neurology. (2007) 68, no. 14, 1108–1115, 2-s2.0-34147154059, https://doi.org/10.1212/01.wnl.0000258660.74391.c1.
82Sethi K. D.,
Hauser R. A., and
Earl N. L., Ropinirole 24-hour prolonged release improves disease-specific and global symptoms when used as adjunctive therapy to levodopa in patients with advanced Parkinson′s disease, Movement Disorders. (2006) 21, no. supplement 15.
83Sethi K. D.,
Stocchi F., and
Giorgi L., Ropinirole 24-hour prolonged release in advanced Parkinson′s disease: relationship between treatment response and disease severity, Movement Disorders. (2007) 22, no. supplement 16.
84Stacy M. A.,
Pahwa R., and
Earl N. L., Ropinirole 24-hour prolonged release reduces “off” time and the dose of levodopa needed when used as adjunctive therapy in patients with advanced Parkinson′s disease, Movement Disorders. (2006) 21, no. supplement 15.
85Stocchi F.,
Hersh B. P.,
Earl N. L., and
Scott B. L., Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson′s disease, Movement Disorders. (2006) 21, no. supplement 15.
86Stocchi F.,
Stover N. P., and
Giorgi L., Ropinirole 24-hour prolonged release as adjunct to levodopa in patients with advanced Parkinson′s disease—efficacy according to baseline depression score, Movement Disorders. (2007) 22, no. supplement 16.
87Möller J. C.,
Oertel W. H.,
Köster J.,
Pezzoli G., and
Provinciali L., Long-term efficacy and safety of pramipexole in advanced Parkinson′s disease: results from a European multicenter trial, Movement Disorders. (2005) 20, no. 5, 602–610, 2-s2.0-20844449074, https://doi.org/10.1002/mds.20397.
88Künig G.,
Pogarell O.,
Möller J. C.,
Delf M., and
Oertel W. H., Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson′s disease, Clinical Neuropharmacology. (1999) 22, no. 5, 301–305, 2-s2.0-0345425689.
89Wong K. S.,
Lu C. S.,
Shan D. E.,
Yang C. C.,
Tsoi T. H., and
Mok V., Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson′s disease, Journal of the Neurological Sciences. (2003) 216, no. 1, 81–87, 2-s2.0-0242607873, https://doi.org/10.1016/S0022-510X(03)00217-X.
90Musch B. and
Bonura L., Cabergoline once a day as adjunctive therapy to levodopa in Parkinson′s disease, Movement Disorders. (2000) 15, no. supplement 3.
91Pinter M. M.,
Pogarell O., and
Oertel W. H., Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson′s disease: a double blind, placebo controlled, randomised, multicentre study, Journal of Neurology Neurosurgery and Psychiatry. (1999) 66, no. 4, 436–441, 2-s2.0-0033046354.
92Wermuth L., A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson′s disease, European Journal of Neurology. (1998) 5, no. 3, 235–242, 2-s2.0-0031832130.
93Lieberman A.,
Ranhosky A., and
Korts D., Clinical evaluation of pramipexole in advanced Parkinson′s disease: results of a double-blind, placebo-controlled, parallel-group study, Neurology. (1997) 49, no. 1, 162–168, 2-s2.0-0030753601.
94Weiner W. J.,
Factor S. A.,
Jankovic J.,
Hauser R. A.,
Tetrud J. W.,
Waters C. H.,
Shulman L. M.,
Glassman P. M.,
Beck B.,
Paume D., and
Doyle C., The long-term safety and efficacy of pramipexole in advanced Parkinson′s disease, Parkinsonism and Related Disorders. (2001) 7, no. 2, 115–120, 2-s2.0-0035119862, https://doi.org/10.1016/S1353-8020(00)00031-6.
95Guttman M., Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson′s disease, Neurology. (1997) 49, no. 4, 1060–1065, 2-s2.0-0030726156.
96Kreider M.,
Knox S.,
Gardiner D., and
Wheadon D., A multicenter double-blind study of ropinirole as an adjunct to levodopa in Parkinson′s disease, Neurology. (1996) 46: A475.
97Lieberman A.,
Olanow C. W.,
Sethi K.,
Swanson P.,
Waters C. H.,
Fahn S.,
Hurtig H., and
Yahr M., A multicenter trial of ropinirole as adjunct treatment for Parkinson′s disease, Neurology. (1998) 51, no. 4, 1057–1062, 2-s2.0-0031664919.
98Rascol O.,
Lees A. J.,
Senard J. M.,
Pirtosek Z.,
Brefel C.,
Montastruc J. L., and
Fuell D., A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients, Advances in Neurology. (1996) 69, 531–534, 2-s2.0-0029685213.
99Rascol O.,
Lees A. J.,
Senard J. M.,
Pirtosek Z.,
Montastruc J. L., and
Fuell D., Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson′s disease, Clinical Neuropharmacology. (1996) 19, no. 3, 234–245, 2-s2.0-0029968682.
100Steiger M. J.,
El-Debas T.,
Anderson T.,
Findley L. J., and
Marsden C. D., Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations, Journal of Neurology. (1996) 243, no. 1, 68–72, 2-s2.0-0029655704.
101Hutton J. T.,
Koller W. C.,
Ahlskog J. E.,
Pahwa R.,
Hurtig H. I.,
Stern M. B.,
Hiner B. C.,
Lieberman A.,
Pfeiffer R. F.,
Rodnitzky R. L.,
Waters C. H.,
Muenter M. D.,
Adler C. H., and
Morris J. L., Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson′s disease, Neurology. (1996) 46, no. 4, 1062–1065, 2-s2.0-9244228479.
102Lieberman A. N. and
Hutton J. T., Levodopa sparing effect of cabergoline compared to placebo in patients affected by motor fluctuations, under levodopa therapy, Movement Disorders. (1996) 11, no. supplement 1.
103Schoenfelder J.,
Simons J.,
Souder D. E., and
Bianchine J., A placebo-controlled study of the safety and efficacy of cabergoline in the treatment of Parkinson′s disease, Functional Capacity Evaluation Reports, 1993, no. 21336/731i, Clinical Reference 42.
104Olanow C. W.,
Fahn S.,
Muenter M.,
Klawans H.,
Hurtig H.,
Stern M.,
Shoulson I.,
Kurlan R.,
Grimes J. D.,
Jankovic J.,
Hoehn M.,
Markham C. H.,
Duvoisin R.,
Reinmuth O.,
Leonard H. A.,
Ahlskog E.,
Feldman R.,
Hershey L., and
Yahr M. D., A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet® in Parkinson′s disease, Movement Disorders. (1994) 9, no. 1, 40–47, 2-s2.0-0028054876, https://doi.org/10.1002/mds.870090107.
105Temlett J. A.,
Ming A.,
Saling M.,
Fritz V. U.,
Blumenfeld A.,
Bilchik T. R.,
Becker A. L.,
Fourie P. B., and
Reef H. E., Adjunctive therapy with bromocriptine in Parkinson′s disease, South African Medical Journal. (1990) 78, no. 11, 680–685, 2-s2.0-0025643543.
107Schneider E. and
Fischer P. A., Bromocriptine in the treatment of progressive stages of Parkinson′s disease, Deutsche Medizinische Wochenschrift. (1982) 107, no. 5, 175–179, 2-s2.0-0020079864.
108Jansen E. N. H., Bromocryptine in levodopa response-losing parkinsonism. A double blind study, European Neurology. (1978) 17, no. 2, 92–99, 2-s2.0-0017875190.
109Stocchi F.,
Ruggieri S.,
Vacca L., and
Olanow C. W., Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson′s disease, Brain. (2002) 125, no. 9, 2058–2066, 2-s2.0-0036723589.
110Rinne U. K.,
Bracco F.,
Chouza C.,
Dupont E.,
Gershanik O.,
Marti Masso J. F.,
Montastruc J. L., and
Marsden C. D., Early treatment of Parkinson′s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial, Drugs. (1998) 55, no. supplement 1, 23–30, 2-s2.0-0031985731, https://doi.org/10.2165/00003495-199855001-00004.
111Clarke C. E. and
Deane K. D., Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson′s disease, Cochrane Database of Systematic Reviews. (2001) no. 1, CD001519, 2-s2.0-0035220298.
112Stowe R.,
Ives N.,
Clarke C. E.,
Deane K.,
van Hilten,
Wheatley K.,
Gray R.,
Handley K., and
Furmston A., Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson′s disease patients with motor complications, Cochrane Database of Systematic Reviews. (2010) 7, 2-s2.0-77955501449.
114Metman L. V.,
Del Dotto P.,
van den Munchkof P.,
Fang J.,
Mouradian M. M., and
Chase T. N., Amantadine as treatment for dyskinesias in Parkinson′s disease, Neurology. (1998) 50, no. 5, 1323–1326.
115Lugging E.,
Wenning G. K.,
Bosch S. et al., Beneficial effects of amantadine on levodopa-induced dyskinesias in Parkinson′s disease, Movement Disorders. (2000) 15, 873–878.
116Snow B. J.,
Macdonald L.,
Mcauley D., and
Wallis W., The effect of amantadine on levodopa-induced dyskinesias in Parkinson′s disease: a double-blind, placebo-controlled study, Clinical Neuropharmacology. (2000) 23, no. 2, 82–85, 2-s2.0-0033999316, https://doi.org/10.1097/00002826-200003000-00004.
117Crosby N. J.,
Deane K. H., and
Clarke C. E., Amantadine for dyskinesia in Parkinson′s disease, Cochrane Database of Systematic Reviews. (2003) no. 2, 2-s2.0-18544397907.
118Durif F.,
Debilly B.,
Galitzky M.,
Morand D.,
Viallet F.,
Borg M.,
Thobois S.,
Broussolle E., and
Rascol O., Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study, Neurology. (2004) 62, no. 3, 381–388, 2-s2.0-1042299831.
120Anderson V. C.,
Burchiel K. J.,
Hogarth P.,
Favre J., and
Hammerstad J. P., Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease, Archives of Neurology. (2005) 62, no. 4, 554–560, 2-s2.0-16844371374, https://doi.org/10.1001/archneur.62.4.554.
121Ford B.,
Winfield L.,
Pullman S. L.,
Frucht S. J.,
Du Y.,
Greene P.,
Cheringal J. H.,
Yu Q.,
Cote L. J.,
Fahn S.,
McKhann G. M., and
Goodman R. R., Subthalamic nucleus stimulation in advanced Parkinson′s disease: blinded assessments at one year follow up, Journal of Neurology, Neurosurgery and Psychiatry. (2004) 75, no. 9, 1255–1259, 2-s2.0-4344612542, https://doi.org/10.1136/jnnp.2003.027557.
122Østergaard K.,
Sunde N., and
Dupont E., Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson′s disease and motor fluctuations, Movement Disorders. (2002) 17, no. 4, 693–700, 2-s2.0-0036651238, https://doi.org/10.1002/mds.10188.
123Moro E.,
Scerrati M.,
Romito L. M. A.,
Roselli R.,
Tonali P., and
Albanese A., Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson′s disease, Neurology. (1999) 53, no. 1, 85–90, 2-s2.0-0033551525.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
